The Stan Bowley Trust was founded by Alan "Stan" Bowley, his family and friends. 

Following his initial cancer diagnosis in 2003, Alan "Stan" Bowley underwent surgery to remove his duodenum and pancreas. The procedure was successful, and as he approached his five-year all-clear milestone, he received devastating news—a secondary tumour had developed, identified as a nerve sheath tumour. Doctors deemed it inoperable, and his oncologist gave him a prognosis of just two years.

Determined to find a way forward, Stan and his wife Janet conducted extensive research and discovered CyberKnife—a pioneering robotic radiotherapy system available in various locations worldwide, predominantly in the United States. They sent Alan’s scans to multiple facilities before receiving confirmation that Washington, D.C., would accept him for treatment.

A former Staffordshire police officer, Stan was met with overwhelming support from family, friends, and colleagues, who rallied together to raise £40,000 to fund his treatment in the U.S. The CyberKnife procedure was a remarkable success, resolving the nerve sheath tumour and granting Stan precious time with his loved ones. He was able to return to work and enjoy family holidays with his three young children—moments he had feared he would never experience.

Tragically, Stan was later diagnosed with a third tumour in his liver, from which he eventually passed away. However, his family has always emphasised that this was unrelated to the CyberKnife treatment, which had been hugely successful in eliminating the nerve sheath tumour. It gave Stan invaluable extra time and the opportunity to create cherished memories with his family.

Before his passing, Alan "Stan" Bowley, together with his family and friends, established the Stan Bowley Trust to raise awareness and funds for CyberKnife technology. This groundbreaking radiotherapy treatment delivers high doses of radiation with sub-millimetre precision, enabling the targeting of previously untreatable tumours. The trust has played a crucial role in expanding access to CyberKnife treatment in the UK, particularly at the Queen Elizabeth Hospital in Birmingham, where over 3,000 patients have received life-changing care.

Today, the trust continues to organise fundraising initiatives and events, striving to support CyberKnife technology while providing vital information to patients and their families. Its mission remains steadfast: to raise awareness of this innovative treatment and ensure more individuals have access to life-changing cancer care.